Literature DB >> 16841524

[Tools for assessing patient perception of the impact of migraine].

Abdelkader El Hasnaoui1, Adam Doble, Anne-Françoise Gaudin.   

Abstract

Patient-reported outcome, relating to the impact of disease and therapy on the wellbeing of the patient, has become an essential part of medicine, guiding enlightened public health policy and resource attribution. Assessment of patient-reported outcome requires the development of specific and validated instruments, generally questionnaires completed by the patient. In the case of migraine, a number of such specific instruments have been developed to measure severity, associated disability, effects on quality of life and overall impact of headache. In addition, generic quality of life measures have allowed migraine to be compared with other pathologies. For example, using the SF-36 generic health-related quality of life profile, quality of life has been shown to be negatively associated with headache severity, impacted more by migraine headaches than by other forms of episodic headache, and diminished to a similar degree in migraine and in other chronic disorders such as depression. Migraine-specific quality of life measures have also been developed, and these are more sensitive to change than generic measures. An example is the QVM scale that has been used to demonstrate an improvement in quality of life following treatment with a triptan. Moreover, quality of life scores on this measure are inversely related to the economic cost of migraine. Disability associated with migraine can be measured using the MIDAS scale. Disability has been shown to be determined by the frequency and severity of headaches and by the headache syndrome itself, with migraine causing more disability than other forms of episodic headache. The MIDAS scale has been used to develop treatment strategies stratified on the level of disability. The severity of individual headaches can be quantified using the MIGSEV scale. The severity of individual headaches has been shown to be closely associated with overall disability, quality of life and overall healthcare expenditure. Finally, the global impact of headaches is measured using the HIT-6 questionnaire, which discriminates well between different headache types and is again closely related to quality of life. These and other measures of the patient's perception of migraine have allowed an ever more precise picture of this multifacetted disorder to be drawn.

Entities:  

Mesh:

Year:  2006        PMID: 16841524

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   6.497


  35 in total

1.  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.

Authors: 
Journal:  Cephalalgia       Date:  1988       Impact factor: 6.292

2.  Reliability of an illness severity measure for headache in a population sample of migraine sufferers.

Authors:  W F Stewart; R B Lipton; D Simon; M Von Korff; J Liberman
Journal:  Cephalalgia       Date:  1998-01       Impact factor: 6.292

3.  Reliability of the migraine disability assessment score in a population-based sample of headache sufferers.

Authors:  W F Stewart; R B Lipton; K Kolodner; J Liberman; J Sawyer
Journal:  Cephalalgia       Date:  1999-03       Impact factor: 6.292

Review 4.  The role of headache-related disability in migraine management: implications for headache treatment guidelines.

Authors:  R B Lipton; S D Silberstein
Journal:  Neurology       Date:  2001       Impact factor: 9.910

Review 5.  Assessing the impact of migraine.

Authors:  A J Dowson
Journal:  Curr Med Res Opin       Date:  2001       Impact factor: 2.580

6.  A six-item short-form survey for measuring headache impact: the HIT-6.

Authors:  M Kosinski; M S Bayliss; J B Bjorner; J E Ware; W H Garber; A Batenhorst; R Cady; C G H Dahlöf; A Dowson; S Tepper
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

Review 7.  Diagnosing the severe headache.

Authors:  D J Dalessio
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

8.  [Quality of life and migraine. Validation of the QVM questionnaire in hospital consultation and in general medicine].

Authors:  A Richard; P Henry; G Chazot; H Massiou; S Tison; R Marconnet; A Chicoye; H d'Allens
Journal:  Therapie       Date:  1993 Mar-Apr       Impact factor: 2.070

9.  Development of a brief 24-hour migraine-specific quality of life questionnaire.

Authors:  S L Hartmaier; N C Santanello; R S Epstein; S D Silberstein
Journal:  Headache       Date:  1995-06       Impact factor: 5.887

10.  Assessment of migraine severity using the MIGSEV scale: relationship to migraine features and quality of life.

Authors:  A El Hasnaoui; M Vray; P Blin; F Nachit-Ouinekh; F Boureau
Journal:  Cephalalgia       Date:  2004-04       Impact factor: 6.292

View more
  5 in total

1.  Comparison of expected outcomes between patients and neurologists using Kano's methodology in symptomatic migraine treatment.

Authors:  J Matías-Guiu; M T Caloto; G Nocea
Journal:  Patient       Date:  2012       Impact factor: 3.883

2.  Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine.

Authors:  Min Yang; Regina Rendas-Baum; Sepideh F Varon; Mark Kosinski
Journal:  Cephalalgia       Date:  2010-09-06       Impact factor: 6.292

3.  Validity and reliability of the Portuguese version of the modified Migraine Disability Assessment.

Authors:  Pedro L Ferreira; Isabel Luzeiro; Margarida Lopes; André Jorge; Bruno Silva; Lara Ferreira
Journal:  BMC Neurol       Date:  2021-02-06       Impact factor: 2.474

4.  Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study.

Authors:  Andrew M Blumenfeld; James P Boyd
Journal:  BMC Neurol       Date:  2022-03-04       Impact factor: 2.474

5.  Validation of the Spanish version of the migraine disability assessment questionnaire (MIDAS) in university students with migraine.

Authors:  Daniel Rodríguez-Almagro; Alexander Achalandabaso; Alma Rus; Esteban Obrero-Gaitán; Noelia Zagalaz-Anula; Rafael Lomas-Vega
Journal:  BMC Neurol       Date:  2020-02-24       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.